10x Genomics Q2 Earnings Exceed Expectations, Stock Surges

10x Genomics reported Q2 CY2025 revenue of $172.9 million, up 12.9% YoY and beating analyst estimates by 24%. However, next quarter's revenue guidance of $142 million fell 1.5% short of analyst expectations. The company's GAAP profit of $0.28 per share was significantly above consensus estimates.

10x Genomics (TXG) reported quarterly earnings and revenue for the period ending June 2025, marking a significant improvement over the previous year. The company's adjusted earnings per share (EPS) of $0.28 surpassed the Zacks Consensus Estimate of a loss of $0.35 per share, representing an earnings surprise of +180.00% [1]. This quarterly report also saw the company's revenue reach $172.91 million, up 12.9% year-over-year (YoY) and beating analyst estimates by 24.00% [1].

However, the company missed its revenue guidance for the next quarter, with the guidance of $142 million falling 1.5% short of analyst expectations of $145.4 million [2]. Despite this, 10x Genomics has shown consistent performance, surpassing consensus EPS estimates three times over the last four quarters [1].

The company's stock has shown resilience despite underperforming the S&P 500 this year, losing about 11.8% since the beginning of the year compared to the S&P 500's gain of 7.9% [1].

Investors should keep an eye on the company's earnings outlook and management's commentary on the earnings call to gauge the stock's immediate price movement. The Zacks Rank, which incorporates earnings estimate revisions, currently rates 10x Genomics as a #2 (Buy) [1].

The outlook for the Medical Info Systems industry, in which 10x Genomics operates, is favorable, with the industry ranking in the top 37% of the 250 plus Zacks industries [1].

Tempus AI (TEM), another healthcare technology company in the same industry, is expected to report its results on August 8. The company is anticipated to post a quarterly loss of $0.23 per share, representing a year-over-year change of +63.5% [1].

Investors should consider the broader industry trends and the company's specific performance when evaluating 10x Genomics as an investment opportunity.

References:

[1] https://www.nasdaq.com/articles/10x-genomics-txg-surpasses-q2-earnings-and-revenue-estimates
[2] https://finance.yahoo.com/news/earnings-watch-10x-genomics-txg-030947742.html